Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Terns Pharmaceuticals Inc (NASDAQ: TERN) closed at $7.54 up 0.13% from its previous closing price of $7.53. In other words, the price has increased by $0.13 from its previous closing price. On the day, 0.81 million shares were traded. TERN stock price reached its highest trading level at $7.64 during the session, while it also had its lowest trading level at $7.25.
Ratios:
For a deeper understanding of Terns Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.70 and its Current Ratio is at 24.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 01 ’25 when Kuriakose Emil sold 853 shares for $4.27 per share. The transaction valued at 3,640 led to the insider holds 52,464 shares of the business.
Gengos Andrew bought 10,000 shares of TERN for $39,283 on Jun 27 ’25. The Chief Financial Officer now owns 25,000 shares after completing the transaction at $3.93 per share. On Jun 25 ’25, another insider, Burroughs Amy L., who serves as the Chief Executive Officer of the company, bought 23,314 shares for $3.87 each. As a result, the insider paid 90,230 and bolstered with 47,083 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TERN now has a Market Capitalization of 659833280 and an Enterprise Value of 345521312.
Stock Price History:
The Beta on a monthly basis for TERN is -0.04, which has changed by -0.21540064 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, TERN has reached a high of $10.69, while it has fallen to a 52-week low of $1.87. The 50-Day Moving Average of the stock is 15.20%, while the 200-Day Moving Average is calculated to be 62.61%.
Shares Statistics:
For the past three months, TERN has traded an average of 1.08M shares per day and 1142310 over the past ten days. A total of 87.47M shares are outstanding, with a floating share count of 69.58M. Insiders hold about 20.49% of the company’s shares, while institutions hold 83.03% stake in the company. Shares short for TERN as of 1756425600 were 7857238 with a Short Ratio of 7.29, compared to 1753920000 on 6729143. Therefore, it implies a Short% of Shares Outstanding of 7857238 and a Short% of Float of 8.979999.
Earnings Estimates
A detailed examination of Terns Pharmaceuticals Inc (TERN) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.24 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.06 and -$1.25 for the fiscal current year, implying an average EPS of -$1.13. EPS for the following year is -$1.25, with 10.0 analysts recommending between -$0.75 and -$1.5.
